Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

2.281 -0.199 (-8.02%)
Streaming Delayed Price Updated: 11:35 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ALX Oncology Holdings Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development 
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces November Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual... 
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal antibody in patients with multiple myeloma 
From ALX Oncology
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗
 
Via Benzinga
News headline image
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q2 2024 ↗
ALXO stock results show that ALX Oncology Holdings beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
From ALX Oncology
Via GlobeNewswire
News headline image
Crude Oil Moves Lower; Moderna Shares Plunge ↗
 
Via Benzinga
News headline image
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July ↗
 
Via Benzinga
Topics Stocks
News headline image
Nasdaq Surges 1%; Meta Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients ↗
ALX Oncology announces Phase 2 ASPEN-06 trial results for evorpacept in combination with trastuzumab, Cyramza, and paclitaxel for HER2-positive gastric/GEJ cancer. The trial shows significant... 
Via Benzinga
News headline image
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
News headline image
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024 ↗
ALXO stock results show that ALX Oncology Holdings beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Appoints Allison Dillon as Chief Business Officer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
From ALX Oncology
Via GlobeNewswire
News headline image
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.